Inovio looks to raise up to $125M; Sunesis sets sights on $43M: Epizyme earns $2M milestone from GSK;

@FierceBiotech: Radius Health looks to catch the IPO wave with $86M pitch. News | Follow @FierceBiotech

@JohnCFierce: Generics manufacturing--the "Wild West." I'm telling you, this is a scandal in the making. Piece via Bloomberg | Follow @JohnCFierce

@DamianFierce: Analyst: Merck's PD-1 promise could heap $5B on 2020 revenue. Story | Follow @DamianFierce

@EmilyMFierce: NIH makes new database on age-related diseases available to researchers. Item | Follow @EmilyMFierce

> Blue Bell, PA-based Inovio Pharmaceuticals ($INO) has filed to sell up to $125 million in shares periodically to help fund its work on DNA-based vaccines. Report

> South San Francisco-based Sunesis Pharmaceuticals is raising $43 million in a follow-on offering. Release

> Salix Pharmaceuticals ($SLXP) has struck a deal to license the worldwide rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and other purgative developments. The deal includes an upfront payment of $7 million and $5 million in subsequent milestone payments to RedHill. Release

> Epizyme ($EPZM) says it has earned a $2 million milestone from its partnership with GlaxoSmithKline ($GSK). Release

> Pacira Pharmaceuticals ($PCRX) says that its Phase III study of its pain drug Exparel met its primary endpoint for femoral nerve block. Release

Medical Device News

@FierceMedDev: A proposed reform of the tax code would also repeal the 2.3% medical device tax. Naturally, the industry likes. Story | Follow @FierceMedDev

@MarkHFierce: New research suggests that pacers and the like are safe for CT scans, contrary to FDA fears. Item | Follow @MarkHFierce

@MichaelGFierce: From this week's FierceDrugDelivery report: Inner-ear delivery device sends drugs out, draws fluid in. More | Follow @MichaelGFierce

@EmilyWFierce: FDA calls for first major redrawing of food labels since the '90s, putting calorie counts front and center. Article | Follow @EmilyWFierce

> Researchers chide FDA: Pacemaker patients need not fear a CT scan. News

> FDA eyes March for Staar ocular implant review. Story

> Covidien closes its $860M Given Imaging buyout. More

Pharma News

@FiercePharma: Bayer's OTC growth march continues with pickup of China's Dihon. Story | Follow @FiercePharma

@TracyStaton: If you can't get enough of the transition at Novartis: Gist: Shareholders speak at AGM; they like the pay cuts. News (sub. req.) | Follow @TracyStaton

@EricPFierce: No sooner does Commish Hamburg return from India than the FDA reveals a new warning letter about data faking there. More | Follow @EricPFierce

@CarlyHFierce: Via FierceBiotech: Regeneron's Schleifer hits the $1B mark, but his biotech is just getting started. Article | Follow @CarlyHFierce

> FDA spying may have broken whistleblower laws, congressional probe finds. News

> FDA and EMA join forces to diffuse safety cloud over Januvia, Victoza & Co. Story

> J&J's high-stakes argument against $1.2B Risperdal fine begins in Arkansas' top court. Piece

Pharma Manufacturing News

> Mylan earnings point to reason for Agila deal. Report

> Bayer expands production in China by bagging Dihon. News

> Pfizer gets past shortage of hypothyroid drug Levoxyl. Story

> Critics call for harsher treatment of foreign drugmakers who sell faulty drugs. Article

> Doc goes to jail for lying about foreign-sourced Botox. Story

> AstraZeneca's Delaware campus sold to JPMorgan. Brief

Vaccines News

> H1N1's dominance this flu season makes quadrivalent vaccines' broader protection moot. Story

> Pfizer reports its huge trial of Prevnar has met its primary and secondary goals. News

> CDC is 'not unduly alarmed' by cases of a polio-like illness in California. Story

> Data mining study links seasonal flu vaccine to 24% drop in likelihood of stroke. Research

> MMR vaccine linked to fall in respiratory-related hospitalizations. Investigation

> Taiwan's Adimmune targets June start for mass production of bird flu vaccine. Brief

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.